SCHEMBL24258073

SCHEMBL24258073

c1ccc2cc(Cc3nc(-c4ccncc4)no3)ccc2c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 3/20 0.72
KDM4E B2RXH2 1/20 0.64
RAB9A P51151 6/20 0.56
SMN1; SMN2 Q16637 6/20 0.54
NPC1 O15118 5/20 0.54
L3MBTL1 Q9Y468 3/20 0.54
TDP1 Q9NUW8 2/20 0.54
S1PR3 Q99500 1/20 0.54
TSHR P16473 2/20 0.53
LMNA P02545 1/20 0.53
NR2F2 P24468 1/20 0.53
STAT3 P40763 1/20 0.53
HTT P42858 1/20 0.53
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
HSD17B10 Q99714 1/20 0.52
ALDH1A1 P00352 1/20 0.49
MAPT P10636 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26004648 0.90 RAB9A (0.66) S1PR1KDM4ERAB9ASMN1; SMN2NPC1
SCHEMBL13416534 0.84 S1PR1 (1.00) S1PR1KDM4ERAB9ASMN1; SMN2NPC1
SCHEMBL24258087 0.81 S1PR1 (0.63) S1PR1KDM4ERAB9ASMN1; SMN2NPC1
SCHEMBL24258086 0.80 S1PR1 (0.70) S1PR1KDM4ERAB9ASMN1; SMN2NPC1
SCHEMBL24258078 0.78 CYP1A2 (0.50) S1PR1RAB9ASMN1; SMN2NPC1L3MBTL1
SCHEMBL26004974 0.78 L3MBTL1 (0.53) S1PR1RAB9ASMN1; SMN2NPC1L3MBTL1
SCHEMBL13416827 0.75 SMN1; SMN2 (0.79) S1PR1KDM4ERAB9ASMN1; SMN2NPC1
SCHEMBL7598545 0.74 S1PR1 (0.81) S1PR1RAB9ASMN1; SMN2NPC1L3MBTL1
SCHEMBL7403511 0.73 CYP3A4 (0.53) RAB9ACYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL26004943 0.73 MAPK1 (0.67) S1PR1RAB9ASMN1; SMN2NPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
WO-2022035805-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP1, USP18 S1PR1 4154/4885KDM4E 1199/4885RAB9A 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.